Technical Analysis for MVRBF - Medivir Ser B Sek5

Grade Last Price % Change Price Change
grade A 1.35 0.00% 0.0000
MVRBF closed unchanged on Tuesday, April 7, 2020, on 18 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A N/A Up
Historical MVRBF trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 12.50%
Wide Bands Range Expansion 12.50%
Gapped Up Strength 12.50%
Older signals for MVRBF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Europe, the Nordic region, the United States, and the rest of the world. The company's products portfolio includes Remetinostat, which has completed Phase II clinical study for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytruda that is in phase I/II study for treating solid tumors; and MIV-711, which is in Phase IIa study that is used for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include Xerclear for use in the treatment of labial herpes in Europe and the rest of the world; MIV-802, a pan-genotypic nucleotide-based inhibitor of the hepatitis C virus NS5B polymerase, which is in preclinical development in Greater China; and Simeprevir/OLYSIO, an antiviral combination treatment regimen for chronic genotype 1 and 4 hepatitis C infection in adult patients with liver disease, including cirrhosis. Medivir AB (publ) was founded in 1988 and is headquartered in Huddinge, Sweden.
Chemistry Medicine RTT Pharmaceuticals Solid Tumors Osteoarthritis Organic Chemistry Healthcare Associated Infections Infectious Causes Of Cancer Cyclopropanes Hepatitis C Hepatocellular Carcinoma Liver Disease Cirrhosis Cutaneous T Cell Lymphoma Sulfonamides Treatment Of Osteoarthritis Treatment Of Cutaneous T Cell Lymphoma

Is MVRBF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.5
52 Week Low 1.12
Average Volume 5,609
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 1.5255
10-Day Moving Average 1.3220
Average True Range 0.1862
ADX 50.75
+DI 26.5546
-DI 67.7293
Chandelier Exit (Long, 3 ATRs ) 1.2914
Chandelier Exit (Short, 3 ATRs ) 1.6786
Upper Bollinger Band 1.9802
Lower Bollinger Band 1.0708
Percent B (%b) 0.31
BandWidth 59.6132
MACD Line -0.5437
MACD Signal Line -0.6759
MACD Histogram 0.1322
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.3500
Resistance 3 (R3) 1.3500 1.3500 1.3500
Resistance 2 (R2) 1.3500 1.3500 1.3500 1.3500
Resistance 1 (R1) 1.3500 1.3500 1.3500 1.3500 1.3500
Pivot Point 1.3500 1.3500 1.3500 1.3500 1.3500
Support 1 (S1) 1.3500 1.3500 1.3500 1.3500 1.3500
Support 2 (S2) 1.3500 1.3500 1.3500 1.3500
Support 3 (S3) 1.3500 1.3500 1.3500
Support 4 (S4) 1.3500